잠시만 기다려 주세요. 로딩중입니다.


Newborn screening for galactosaemia
Rohollah Lak, Bahareh Yazdizadeh, Majid Davari, Mojtaba Nouhi, Roya Kelishadi
23 December 2017
검토그룹 : 낭성 섬유증과 유전자질환그룹(Cystic Fibrosis and Genetic Disorders Group)
코크란링크 :

Background

Classical galactosaemia is an autosomal recessive inborn error of metabolism caused by a deficiency of the enzyme galactose-1-phosphate uridyltransferase. This is a rare and potentially lethal condition that classically presents in the first week of life once milk feeds have commenced. Affected babies may present with any or all of the following: cataracts; fulminant liver failure; prolonged jaundice; or Escherichia coli sepsis. Once the diagnosis is suspected, feeds containing galactose must be stopped immediately and replaced with a soya-based formula. The majority of babies will recover, however a number will not survive. There are long-term complications of galactosaemia, despite treatment, including learning disabilities and female infertility. It has been postulated that galactosaemia could be detected on newborn screening and this would prevent the immediate severe liver dysfunction and sepsis.

Objectives

To assess whether there is evidence that newborn screening for galactosaemia prevents or reduces mortality and morbidity and improves clinical outcomes in affected neonates and the quality of life in older children.

Search methods

We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from electronic database searches, handsearches of relevant journals and conference abstract books. We also searched online trials registries and the reference lists of relevant articles and reviews.

Date of the most recent search of Cochrane Cystic Fibrosis Group’s Trials Register: 18 December 2017.

Date of the most recent search of additional resources: 11 October 2017.

Selection criteria

Randomised controlled studies and controlled clinical studies, published or unpublished comparing the use of any newborn screening test to diagnose infants with galactosaemia and presenting a comparison between a screened population versus a non-screened population.

Data collection and analysis

No studies of newborn screening for galactosaemia were found.

Main results

No studies were identified for inclusion in the review.

Authors’ conclusions

We were unable to identify any eligible studies for inclusion in this review and hence it is not possible to draw any conclusions based on randomised controlled studies. However, we are aware of uncontrolled studies which support the efficacy of newborn screening for galactosaemia. There are a number of reviews and economic analyses of non-trial literature suggesting that screening is appropriate.

교신저자
Rohollah Lak
lak2346@yahoo.com
Vice-Chancellery for Health, Isfahan University of Medical Sciences, Isfahan, Iran.